CITAGENIX INC. – Trademark Portfolio
Entity Type: 03
CITAGENIX INC. holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 6 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 4 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include RAPTOS, BONTEMPI, CITAGENIX, PENTOS OI, and PRESERVARIDGE. The owner is based in Laval, Quebec.
A-440 O
3300 Autoroute Jean-Noel Lavoie
Laval, Quebec H7T2H6 , CA
Showing of trademarks Trademarks
Trademark Classifications
CITAGENIX INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Education; providing of training; entertainment; sporting and cultural activities
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does CITAGENIX INC. have?
CITAGENIX INC. has 11 U.S. trademarks filed with the USPTO. Of these, 7 registered, 4 cancelled.
What trademark classes does CITAGENIX INC. file in?
CITAGENIX INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 35 (Advertising & Business), Class 41 (Education & Entertainment), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are CITAGENIX INC.'s most well-known trademarks?
CITAGENIX INC.'s registered trademark portfolio includes well-known marks such as RAPTOS, BONTEMPI, CITAGENIX, PENTOS OI, and PRESERVARIDGE. These are among 7 currently registered trademarks in the portfolio.
What is CITAGENIX INC.'s trademark registration success rate?
CITAGENIX INC. has a 64% trademark registration rate, with 7 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.